PD 168368 is primarily utilized in research settings as a selective inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinases. Its application is significant in studying the role of FGFR signaling pathways in various biological processes, including cell proliferation, differentiation, and survival. Researchers employ PD 168368 to investigate its potential therapeutic effects in diseases where FGFR signaling is dysregulated, such as certain types of cancers. By inhibiting FGFR activity, it helps in understanding the molecular mechanisms underlying tumor growth and progression, thereby aiding in the development of targeted cancer therapies. Additionally, PD 168368 is used in preclinical studies to evaluate its efficacy and safety as a potential drug candidate for treating conditions associated with abnormal FGFR signaling.